Vaccines for prevention of splenic fever and necrotic stomatitis in animals and method for its preparation |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
IPC classes for russian patent Vaccines for prevention of splenic fever and necrotic stomatitis in animals and method for its preparation (RU 2524430):
 Immunogenic composition applicable for staphylococcus vaccination / 2521501
Invention refers to immunology, molecular biology and genetic engineering. There are presented an immunogenic composition containing a mixture of staphylococcal proteins, and comprising a staphylococcal protein binding an extracellular component, and a staphylococcal transport protein, or the staphylococcal protein binding the extracellular component, and a staphylococcal virulence regulator or a toxin, or the staphylococcal transport protein and the staphylococcal virulence regulator or the toxin. There are also presented vaccines, methods of treating, using and methods for preparing a staphylococcus vaccine.
Associated salmonellosis, escherichiosis and rabbit viral haemorrhagic disease vaccine / 2510839
Invention refers to veterinary medicine, and concerns an associated salmonellosis, escherichiosis and rabbit viral haemorrhagic disease vaccine. The presented vaccine contains antigens in the form of pure-growth suspended cells of salmonellosis Sal.typhimurium, escherichiosis E.coli and rabbit viral haemorrhagic disease prepared from target affected organ of dead rabbits in a local epizootic centre; the vaccine also contains glucose, formalin and aluminium hydroxide in the specified amounts.
 Compositions containing neisseria meningitidis serogroup b and c antigens, and additional antigen / 2508122
Invention discloses an immunogenic composition having an immunogenic activity on serogroup B and C Neisseria meningitidis containing (a) N. meningitidis serogroup C (NmC) oligosaccharide, (b) proteoliposome vesicles of the outer membrane of N.meningitidis (NmB) serogroup B and (c) NmB protein containing and an amino acid sequence presented in the description, or an immunogenic fragment of the above sequence, or a sequence min. 80% identical to the above sequence. The ingredient (a) may be conjugated with a carrier, e.g. with a protein, CRM197, a diphtherial anatoxin or a tetanus anatoxin. The immunogenic composition can contain aluminium hydroxide or MF59 as an adjuvant. What is described is a N.meningitidis serogroup B and C vaccine containing the described immunogenic composition.
Method for producing associated salmonellosis, escherichiosis and rabbit viral hemorrhagic disease vaccine / 2496518
Invention refers to veterinary medicine, and concerns a method for producing an associated salmonellosis, escherichiosis and rabbit viral hemorrhagic disease vaccine. Implement the method involves sampling the affected organs from fallen rabbits on the local epidemical block to prepare a suspension that is followed by inoculation of differential diagnostic media. Pure cultures of pathogens are recovered. The culture Salmonella typhimurium, Escherichia coli is separately grown in meat infusion broth with adding glucose to the concentration of 0.2% with a titre of 4-5 bln. microbial cells in 1 cm3. Then the rabbits are infected with a hemorrhagic disease virus at min. activity 103 LD50/cm3 and the fallen rabbits' liver is used to prepare 10-15% suspension. The pathogen cultures are inactivated separately in formalin to the final concentration of no more than 0.4% at temperature 37°C for no more than 4 days; the inactivated culture mixture is added with an adjuvant which is presented by an aluminium hydroxide gel in the amount of 20% to the volume; the end product is thoroughly mixed before packaging.
Method of treating chronic non-specific endometritis / 2493863
Invention refers to medicine, namely gynaecology, and may be used for treating the patients with chronic non-specific endometritis. The method is implemented as follows: a therapeutic agent that is polyvalent complex pyobacteriophage in a dose of 4-7 ml is introduced in a female patient with a completely empty bladder on the 5-7th postmenstrual day. There are 5 procedures of administering pyobacteriophage required. That is followed by the exposure to low-intensity infrared pulse laser at wave length 0.89 mcm, frequency 80 Hz, pulse power 5 Wt; the cutaneous daily 10-minute exposure covers the underbelly. For the 5 of 10 minutes, the exposure covers a projection of the uterus, while for the rest 5 minutes, a projection of the annexes are exposed. The therapeutic course is 10 procedures. Besides, the underbelly exposure is combined with the daily exposure covering a projection of the cubital vessels and the suprasternal notch for 2-3 minutes with the therapeutic course making 10 procedures. The exposure on a projection of the cubital vessels and the suprasternal notch may be both combined with the underbelly exposure, and follow the same.
Associated vaccine for prevention of anthrax and necrobacillosis in animals / 2480237
Invention refers to veterinary science and biotechnology, and concerns preparing an associated vaccines for prevention of anthrax and necrobacillosis in animals. The characterized vaccine contains the following ingredients in proportions, wt %: a suspension of living spores of the anthrax vaccine strain 55-VNIIVViM (All-Russian Research Institution of Virology and Microbiology) with the initial concentration of (5-5.2)X107 in physiologic saline 1 cm3 - 1.0-1.2; -saponin - 1.5-2.1; -formalin-inactivated leukocidin - exotoxin with molecular weight 18-20 kDa of the strain of Fusobacterium necrophorum "0-1" VIEV (All-Russian Institution of Experimental Virology with the protein content of 5.5- 6 mg % adsorbed in 12-15% aluminium hydroxide taken in the final concentration of 1.8-2.0% pre-suspended in glycol buffer with pH 8.4-8.6 - the rest.
 Multiple vaccination including serogroup c meningococci / 2457858
Group of inventions refers to medicine, and concerns multiple vaccination including serogroup C meningococci. Substance of the group of inventions involves an immunisation kit containing a first immunogenic component representing a conjugated capsular saccharide of the strain OAc+ Neisseria meningitides serogroup C and a lyophilised conjugated antigen Hib, and a second immunogenic component containing an aqueous formulation of diphtheria toxoid, tetanus toxoid and cell-free antigen B. pertussis. The invention also involves the application of the lyophilised capsular saccharide of the strain OAc+ Neisseria meningitides serogroup C conjugated with the carrier-protein tetanus toxoid and the aqueous cell-free antigen B. pertussis, for preparing an immunisation drug.
 Saccharide conjugated vaccines / 2454244
Invention discloses compositions for inducing an immune response in a patient, containing a combination of two or more monovalent conjugates wherein each of the monovalent conjugates contains a carrier protein N19 conjugated with a saccharide antigen of the serogroups A, C, W135 or Y Neissera meningitides. A molecule of the carrier protein in the monovalent conjugate is preferred to be conjugated with more than one molecule of the saccharide antigen. Besides, the invention discloses a multivalent conjugate for inducing an immune response in a patient, containing two or more antigen-different saccharide antigens of the serogroups A, C, W135 or Y Neissera meningitides conjugated with the carrier protein N19. The compositions may contain one or more said monovalent conjugates and one or more said multivalent conjugates. The invention shows applicability of the multivalent conjugate and compositions in preparing a medicine for enhancing the immune response in a patient.
 Immunogenic compositions containing lawsonia intracellulars / 2443430
Group of inventions refers to veterinary immunology. A combined vaccine of i) an avirulent isolate of Lawsonia intracellularis and ii) attenuated bacteria of Salmonella spp. effective for treating and/or preventing an infection caused by Salmonella spp., and iii) attenuated bacteria of Erysipelothrix rhsiopathiae effective for treating and/or preventing an infection caused by Erysipelothrix rhsiopathiae with such combined vaccine to be introduced in an animal which is other than a human for treating, preventing an infection and/or for relieving clinical symptoms caused by Salmonella spp. and Erysipelothrix rhsiopathiae Kits containing said immunological agents in one or more containers.
 Combined vaccines with low-dose hib conjugate / 2435609
Invention refers to medicine, and concerns combined vaccines with a low-dose HIB conjugate. The substance of the invention includes the combined vaccines containing diphtheria, tetanus, whooping cough and HIB immunisation antigens (DTP-HIB vaccines), in which: (a) Hib protection antigen represents a capsular saccharide Hib conjugate; (b) the concentration of Hib conjugate in the vaccine makes 1.25 to less than 15 mcg/ml; and (c) Hib conjugate is never lyophilised.
Associated vaccine for prevention of anthrax and necrobacillosis in animals / 2480237
Invention refers to veterinary science and biotechnology, and concerns preparing an associated vaccines for prevention of anthrax and necrobacillosis in animals. The characterized vaccine contains the following ingredients in proportions, wt %: a suspension of living spores of the anthrax vaccine strain 55-VNIIVViM (All-Russian Research Institution of Virology and Microbiology) with the initial concentration of (5-5.2)X107 in physiologic saline 1 cm3 - 1.0-1.2; -saponin - 1.5-2.1; -formalin-inactivated leukocidin - exotoxin with molecular weight 18-20 kDa of the strain of Fusobacterium necrophorum "0-1" VIEV (All-Russian Institution of Experimental Virology with the protein content of 5.5- 6 mg % adsorbed in 12-15% aluminium hydroxide taken in the final concentration of 1.8-2.0% pre-suspended in glycol buffer with pH 8.4-8.6 - the rest.
Method for producing diagnostic anthrax allergen / 2415941
Method provides recovery of a diagnostic anthrax allergen directly from a concentrated suspension of vegetative cells of a vaccine strain Bac. anthracis STI-1. The strain is grown on a nutrient medium based on a muriatic hydrolyzate of a fish flour by deep cultivation. The produced bacterial mass is washed in a separator to produce the concentrated suspension of vegetative cells. An allergenic protein fraction is recovered by alkaline hydrolysis, and the prepared hydrolyzate is fractioned. A protein allergen fraction is recovered from a supernatant of the recovered fraction by fractioning with an acetic acid solution; further the precipitation containing an end product is dissolved, dialyzed to produce a purified anthrax protein allergen. The preparation is presented in liquid and lyophilised forms.
Method for increase of melioidosis antigens protectivity by cytokines / 2376031
Invention is related to the field of medicine, in particular to microbiology and immunology and may be used in development of vaccine against melioidosis. Substance of method consists in the fact that animals are immunised with surface melioidosis complex, which consists of antigen 6 (AG6) and antigen d, which is injected to animals subcutaneously, twice, with interval of 10 days, in doses of 30 mcg by protein for mice or 150 mcg for rats. Simultaneously with primary immunisation recombinant interferon-γ - ingaron is injected in doses 8 ME for mice or 120 ME for rats, and in case of secondary immunisation, recombinant interleukin-2 - roncoleukin in doses of 0.6 mcg for mice or 10 mcg for rats, besides cytokines are injected to animals subcutaneously, daily, simultaneously with immunisation and in the next 2 days. In 21 days after primary immunisation animals are infected with 4-32 LD50 of highly virulent strain 100 of melioidosis causative agent, in 30 days after infection parametres of animal lethality are identified.
Method for immunoprophylaxis of experimental pseudocholera with entrapped antigens burkholderia pseudomallei / 2373955
Invention refers to medicine, particularly to microbiology and immunology and can be used for immunoprophylaxis of pseudocholera. The method involves antigen pretreatment to mice followed by infection and estimating level of protectivity. Antigens Burkholderia pseudomallei are chosen of superficial antigenic fractions: D, C, F, J, H. Herewith the antigen solution in amount 1.5 ml is mixed with phosphatidyl choline approximately 40 mg and cholesterol in the ratio 7:3 to produce liposomes.
Method of obtaining of anthracic protective antigen / 2340356
Plating of the vaccine strain on a sterile nutrient medium with sodium bicarbonate. Thus administer sodium bicarbonate into a nutrient medium throughout an exponential growth phase at 6-8 hours of the vaccine strain planting. After the planting process termination allocation, concentration and sterilisation of a protective antigen is performed on the equipment of ultra-and microstraining.
 Immunogenic composition (versions) based on recombinant intracellular pathogen / 2337707
Presented are immunogenic compositions including recombinant attenuated intracellular pathogens, e.g. Calmette-Guérin bacillus (CGB). Immunogenic composition specifically includes CGB containing sequenced extrachromosomal nucleic acid which includes gene coding large extracellular mycobacteria protein sized 23.5, 30 and/or 32 kDa, thus large extracellular unmerged mycobacteria protein is superexpressed and secreted. Version is immunogenic composition containing recombinant CGB with controlled growth. Introduction of immunogenic compositions in mammal organism is associated with superexpression and secretion of specified proteins causing immune response of organism to introduced antigene.
 Proteins causing alternated immunogenic response and methods for their preparing and using / 2311458
Invention relates to a variant of protein subtilysine from Bacillus amyloliquiefaciens with change Y217L and comprising T-cellular epitope. This T-cellular epitope of indicated variant comprises one or some amino acid changes chosen from group consisting of residues corresponding to positions: 76, 79 and 122 wherein indicated subtilysine variant has optionally change at one or some following positions: 3, 31, 40, 41, 46, 47, 48, 50, 76, 101, 104, 107, 111, 128, 147, 154, 181, 182, 183, 185, 206, 215, 218, 238, 247, 248, 250, 254, 258 and 262. Also, invention relates to DNA molecules that encode subtilysine variants, host-cells containing this DNA, and to compositions used in skin care and containing indicated subtilysine variants. Invention provides preparing subtilysine variants that elicit reduced immunogenic response in human as compared with the parent subtilysine.
 Method for preparing nontoxic anti-anthrax vaccine / 2287581
Invention relates to producing vaccines and describes anti-anthrax vaccine that comprises mutant protein toxin from Bacillus anthracis chosen from mutant PA or mutant LF, or mutant EF or their combinations. Mutations of toxins provide the retained immunogenicity in decreasing the level of their toxicity. For the development of vaccine with reduced reactivity invention proposes recombinant DNA-construction for expression of said protein-toxins. DNA-construction comprises the expressing vector and DNA fragment comprising, in turn, genes encoding the corresponding protein-toxin (PA, LF or EF). Invention describes a method for preparing mutant proteins by using the transformed prokaryotic host. Prepared mutant protein-toxin possessing immunogenic properties and absence of toxicity is used for preparing anti-anthrax vaccine comprising one or more mutant protein-toxins and in combination with protein-toxin PA, LF or EF of wild type. Using the invention provides to develop the safety and effective vaccine against anthrax.
Associated vaccine against anthrax and plague in cattle / 2286173
The suggested vaccine contains suspension of viable spores of anthracic vaccinal strain "55-VNIIBB&M" at initial concentration of 500-700 mln. spores/cu.cm, cultural virus-containing raw material of vaccinal virus of cattle plague of "LT" strain at activity of not less than 7.0 lg TCD50/cu. cm, lactosopeptonic stabilizing agent and distilled water at the following content of components,%: spores of anthracic strain "55-VNIIVV&M" -6.2 - 10.0; cultural raw material of cattle plague virus of "LT" strain -25.0 - 30.0; lactosopeptonic stabilizing agent -48.0 - 50.0; distilled water - the rest. One vaccinal dosage contains about 20-25 mln. anthracic spores and about 4.5-5.5 lg TCD50 of cattle plague virus The suggested vaccine is of high immunogenicity, develops tense immunity in once vaccinated cattle that lasts for 12 mo, not less, moreover, it is areactogenous, safe and stable at storage.
 Immunogenic polypeptide inducing protective immune response against bacillus anthracis (variants), method for its preparing, nucleic acid encoding thereof, expression vector (variants), method and vaccine for prophylaxis of infection caused by bacillus anthracis / 2270865
Invention relates to a method for preparing an immunogenic polypeptide inducing immune response that represents the protective response against infection with Bacillus anthracis. Proposed immunogenic polypeptide comprises from one to three domains of the full-scale Protective Antigen (PA) from B. anthracis or their variants and at least one of indicated domains represents domain 1 or domain 4 from PA or its variant. These variants of immunogenic polypeptide and full-scale PA are produced as result of expression in E. coli. Also, invention proposes a vector for expression in bacterial cells that comprises nucleic acid encoding abovementioned immunogenic polypeptide. Also, invention the developed method for prophylaxis of infection caused by B. anthracis based on administration of sufficient amount of immunogenic polypeptide. Also, invention proposes a vaccine for prophylaxis of infection caused by B. anthracis that comprises the effective amount of immunogenic polypeptide and a suitable carrier. Invention provides preparing the effective agent used for prophylaxis of infection caused by B. anthracis.
 Method for production of immune serum to virulent strain bacillus anthracis antigen / 2252031
Claimed method includes administering before contamination to the animal subsequently in right pope then after 14 days in left pope 0.2 ml of non-complete Freund's adjuvant with equal volume of physiological salt solution. Subsequent administering after 14 days in right pope up to 10 LD50 of Bacillus anthracis 81/1 spore dredge doesn't cause animal death for long period (monitoring time is 35 days).
|
FIELD: veterinary medicine. SUBSTANCE: presented vaccine comprises the formalin-inactivated leukocidin-exotoxin obtained from production strain Fusobacterium necrophorum "0-1" Russian Research Institute of Experimental Veterinary Medicine ,1-10% inactivated bacterial mass of the said strain containing 7.0-7.7 billion cells per 1 cm3, glycerol and a mixture of mineral oil "Markol-52" and emulsifier taken in weight ratios of 1:(0.9-1.1), and also the suspension of live spores of splenic fever vaccine strain 55 Russian Research Institute of Veterinary Virology and Microbiology in saline, and adjuvant. The method of production of the vaccine comprises cultivation of the strain Fusobacterium necrophorum "0-1" RRIEVM, its inactivation with formalin, isolation of bacterial mass from the culture medium by centrifugation, isolation from the culture medium of exotoxin - leukocidin, its purification and concentration by ultrafiltration on hollow fibres, adding the suspension of live spores of the splenic fever vaccine strain 55-RRIVVM and saponin, and adding of 1-10% inactivated bacterial mass of strain Fusobacterium necrophorum "0-1" RRIEVM, glycerine and mixture of mineral oil "Markol-52" and emulsifier. EFFECT: invention enables to obtain vaccine that provides sustained immunity. 3 cl, 7 ex, 1 tbl
The invention relates to the field of veterinary medicine and biotechnology and the receipt of a vaccine to prevent anthrax and nitrobacteria animals. Known vaccine for the prevention of microbacteria cattle containing equal volume ratios formalin inactivated endotoxin and exotoxin derived from local epizootic cultures of the pathogen microbacteria, and adjuvant on the basis of mineral oil and lanolin (Patent RU 1816348, AK 39/00, 1995). However, the known vaccine is not enough immunogen, as it requires a double injection and provides immunity only against microbacteria for 3.5-4 months. In addition, when receiving vaccines carry out a preliminary selection of local strains for each specific sector, which is not possible in industrial production. Known vaccine against anthrax in animals, containing a suspension of live spores paskapallero avirulent vaccine strain 55-Vniivvim anthrax (THE 9388-004-00008064-99). Known also inactivated vaccine microbacteria animals containing formalin inactivated endotoxin and exotoxin derived from the production strain "0-1" VIEW pathogen microbacteria, and adjuvant on the basis of mineral oil and lanolin (Patent RU 2109519, AK 39/02, 1998). westwoodi single used independently of each other and do not create immunity in animals against anthrax and nitrobacteria. The use of these vaccines separately requires twice the amount of work and has a strong stress animals. Known associated vaccine against anthrax, anaerobic dysentery and infectious enterotoxaemia of sheep containing a suspension of viable spores of the anthrax vaccine strain 55-Vniivvim in the initial concentration (3-4)×108the dispute in 1 cm3, toxoids Cl. perfringens types of source activity 100-150 EU on 1 cm3and D from the source activity 60-80 EU on 1 cm3and saline solution (Patent RU №2191599, IPC7AC 39/116, 2002). However, the known associated vaccine does not provide a sufficient immunity against anthrax and nitrobacteria. Also known vaccine against anthrax and nitrobacteria containing an inactivated by formalin-leukocidin - exotoxin that results from the production of strains of Fusobacterium necrophorum "0-1" VIEW, representing a highly purified protein with a molecular mass of 18-20 kDa and adsorbed on aluminium hydroxide, and the suspension of live spores of the anthrax vaccine strain 55-Vniivvim in saline and adjuvant, and inactivated with formalin-leukocidin - exotoxin adsorbed 12-15% aluminum hydroxide in glycolic acid buffer with a pH of 8.4 and 8.6, taken in the end it is ncentratio 1,8-2,0%, suspension of live spores of the anthrax vaccine strain 55-Vniivvim use with the original concentration (5-5,2)×1071 cm3saline and adjuvant contains saponin at a certain ratio of components (RF Patent No. 2480237, IPC AC 39/116, publ. BI No. 10, 2013), and the way it was received. The objective of the invention is to increase the effectiveness of vaccines against anthrax and nitrobacteria due to increase in terms of immunity of animals. The technical result of the invention is achieved in the vaccine against anthrax and nitrobacteria containing an inactivated by formalin-leukocidin - exotoxin that results from the production of strains of Fusobacterium necrophorum "0-1" VIEW, representing a highly purified protein with a molecular mass of 18-20 kDa and adsorbed on aluminium hydroxide, and the suspension of live spores of the anthrax vaccine strain 55-Vniivvim in saline and adjuvant, characterized in that the suspension of live spores of the anthrax vaccine strain 55-Vniivvim use with the initial concentration (of 2.5-3.0)×1071 cm3saline, optionally contains 1 to 10% inactivated bacterial mass strains of Fusobacterium necrophorum "0-1" VIEW content of 7.0-7.7 billion cells in 1 cm, glycerin and a mixture of mineral oils Marcol-52 and emulsifier taken the x in the weight ratio 1:(0,9-1,1), accordingly, in the following ratio, wt.%:
The technical result of the invention is also achieved in the vaccine against anthrax and nitrobacteria, characterized in that the emulsifier contains emulsifier-139 or ethoxylated With7-C10alkyl phenol. The technical result of the invention is also achieved in a method of producing vaccines against anthrax and nitrobacteria way of the cultivation of strains of Fusobacterium necrophorum "0-1" VIEW, the inaktivirovanie his formalin, division of bacterial mass from the culture fluid by centrifugation, separation from the culture fluid of exotoxin - leukocidin, purification, concentration by ultrafiltration in hollow fibers and adsorption on aluminium hydroxide in glycol buffer, adding a suspension of live spores of the anthrax vaccine strain 55-Vniivvim and saponin, characterized in that before adsorption on aluminium hydroxide to the exotoxin add 1-10% inactivated bacterial mass strains of Fusobacterium necrophorum "0-1" VIEW content of 7.0-7.7 billion cells in 1 cm3and glycerin and a mixture of mineral oils Marcol-52 and emulsifier, taken in the weight ratio 1:(0,9-1,1), respectively, added after the addition of saponin. Know the use of adjuvant mixture Marcola-52 with emulsifier-139 in the ratio of 9:1 (Patent RU №2337706, IPC AC 39/00, bull. No. 31, publ. 10.11.2008). Known also use as emulsifier OP-7 and OP-10 (GOST 8433-81, Patent RU No. 2134964, IPC 01N 25/00, publ. 27.08.1999) - ethoxylated With7-C10the alkyl phenols used to prepare a concentrated emulsion of water-insoluble ingredients. Associated vaccine is administered once cattle, sheep, goats, pigs and the reindeers intradermally using a needleless is njector in the amount of 0,2-0,4 cm 3. Offer associated vaccine against anthrax and nitrobacteria creates long-lasting immunity in vaccinated animals, if it is superior immunogenicity known vaccine against anthrax and nitrobacteria. The vaccine is harmless and avirulent for laboratory and farm animals. A vaccine against anthrax and nitrobacteria prepared as follows. Example 1. To obtain microbacterial antigen - leukocidin - exotoxin take production strain Fusobacterium necrophorum "0-1" VIEW, cultivate, inactivate formalin at a final concentration of 0.4%, separating backass from the culture fluid by centrifugation from the culture fluid secrete an exotoxin which is subjected to high purification by ultrafiltration in hollow fibers with a pore size 13-17 kDa and concentrated to a protein content (Lowry) 5,5-7,0 mg% with a molecular mass of 18-20 kDa. Next, to the resulting antigen - leukocidin - endotoxin add 1-10% inactivated bacterial mass strains of Fusobacterium necrophorum "0-1" VIEW content of 7.0-7.7 billion cells in 1 cm3then adsorb on 12-15% aluminum hydroxide in glycolic acid buffer with a pH of 8.4 and 8.6, taken at a final concentration of 1.8 to 3.0%. After adsorption of the antigen on the hydrate of alumina check the neutralization of the residual formalin. To 54,0 is inactivated by formalin leukocidin - the exotoxin with mm 18-20 kDa from strains of Fusobacterium necrophorum "0-1" VIEW protein content of 5.5 mg%adsorbed 12% aluminum hydroxide in glycolic acid buffer with a pH of 8.4, taken at a final concentration of 1.8%, add 1.0 g of a suspension of live spores of the anthrax vaccine strain 55-Vniivvim with the initial concentration (of 2.5-3.0)×1071 cm3saline solution, 10.0 g of saponin, 20,0 g of glycerin and 15.0 g of a mixture of mineral oils Marcol-52 and emulsifier-139, taken in the weight ratio 1:0,9 receiving structure 1 in the following ratio, wt.%:
The vaccine emuleret in the homogenizer at 3500 rpm for 15 minutes The resulting vaccine is a homogeneous white emulsion. Example 2. To obtain microbacterial antigen - leukocidin - exotoxin take production strain Fusobacterium necrophorum "0-1" VIEW, cultivate, inactivate formalin at a final concentration of 0.4%, separating backass from the culture fluid by centrifugation from the culture fluid secrete an exotoxin which is subjected to high purification by ultrafiltration in hollow fibers with a pore size 13-17 kDa and concentrated to a protein content (Lowry) 5,5-7,0 mg% with a molecular mass of 18-20 kDa. Next, to the resulting antigen - leukocidin - endotoxin add 1-10% inactivated bacterial mass strains of Fusobacterium necrophorum "0-1" VIEW content of 7.0-7.1 billion cells in 1 cm3then adsorb on 12-15% aluminum hydroxide in glycolic acid buffer with a pH of 8.4 and 8.6, taken at a final concentration of 1.8 to 3.0%. After adsorption of the antigen on the hydrate of alumina check the neutralization of the residual formalin. To 33,8 g inactivated by formalin leukocidin - exotoxin with mm 18-20 kDa from strains of Fusobacterium necrophorum "0-1" VIEW protein content of 7.0 mg%adsorbed 15% aluminum hydroxide in g is ikalawa buffer with a pH of 8.4 and 8.6, taken at a final concentration of 3.0%, add 1.2 g of a suspension of live spores of the anthrax vaccine strain 55-Vniivvim with the initial concentration (of 2.5-3.0)×1071 cm3saline solution, 15 g of saponin, 30.0 g of glycerin and 20.0 g of a mixture of mineral oils Marcol-52 and emulsifier-139, taken in the weight ratio 1:1,1 receiving part 2 in the following ratio, wt.%:
The vaccine emuleret in the homogenizer PR is 5000 rpm for 20 minutes The resulting vaccine is a homogeneous white emulsion. Example 3. To obtain microbacterial antigen - leukocidin - exotoxin take production strain Fusobacterium necrophorum "0-1" VIEW, cultivate, inactivate formalin at a final concentration of 0.4%, separating backass from the culture fluid by centrifugation from the culture fluid secrete an exotoxin which is subjected to high purification by ultrafiltration in hollow fibers with a pore size 13-17 kDa and concentrated to a protein content (Lowry) 5,5-7,0 mg% with a molecular mass of 18-20 kDa. Next, to the resulting antigen - leukocidin - endotoxin add 1-10% inactivated bacterial mass strains of Fusobacterium necrophorum "0-1" VIEW content of 7.0-7.7 billion cells in 1 cm3then adsorb on 12-15% aluminum hydroxide in glycolic acid buffer with a pH of 8.4 and 8.6, taken at a final concentration of 1.8 to 3.0%. After adsorption of the antigen on the hydrate of alumina check the neutralization of the residual formalin. To 54.0 per g of inactivated by formalin leukocidin - exotoxin with mm 18-20 kDa from strains of Fusobacterium necrophorum "0-1" VIEW protein content of 5.5 mg%adsorbed 12% aluminum hydroxide in glycolic acid buffer with a pH of 8.4, taken at a final concentration of 1.8%, add 1.0 g of a suspension of live spores of the anthrax vaccine strain 55-Vniivvim with the source end of the acidity (about 2.5-3.0)×10 71 cm3saline solution, 10.0 g of saponin, 20,0 g of glycerin and 15.0 g of a mixture of mineral oils Marcol-52 and OP-7, taken in the weight ratio 1:0,9 receiving part 3 in the following ratio, wt.%:
The vaccine emuleret in the homogenizer at 3500 rpm for 15 minutes The resulting vaccine is a homogeneous white emulsion. Example 4. To obtain microbacterial antigen - leukocidin - catoctin take production strain Fusobacterium necrophorum "0-1" VIEW, cultivate, inactivate formalin at a final concentration of 0.4%, separating backass from the culture fluid by centrifugation from the culture fluid secrete an exotoxin which is subjected to high purification by ultrafiltration in hollow fibers with a pore size 13-17 kDa and concentrated to a protein content (Lowry) 5,5-7,0 mg% with a molecular mass of 18-20 kDa. Next, to the resulting antigen - leukocidin - endotoxin add 1-10% inactivated bacterial mass strains of Fusobacterium necrophorum "0-1" VIEW content of 7.0-7.7 billion cells in 1 cm3then adsorb on 12-15% aluminum hydroxide in glycolic acid buffer with a pH of 8.4 and 8.6, taken at a final concentration of 1.8 to 3.0%. After adsorption of the antigen on the hydrate of alumina check the neutralization of the residual formalin. To 33,8 g inactivated by formalin leukocidin - exotoxin with mm 18-20 kDa from strains of Fusobacterium necrophorum "0-1" VIEW protein content of 7.0 mg%adsorbed 15% aluminum hydroxide in glycolic acid buffer with a pH of 8.4 and 8.6, taken at a final concentration of 3.0%, add 1.2 g of a suspension of live spores of the anthrax vaccine strain 55-Vniivvim with the initial concentration (of 2.5-3.0)×1071 cm3saline solution, 15 g of saponin, 30.0 g of glycerin and 20.0 g of a mixture of mineral oils Marcol-52 and OP-7, taken in the weight ratio 1:1.1, the receiving part 4 when the following ratio is Oseni components, wt.%:
The vaccine emuleret in the homogenizer at 5000 rpm for 20 minutes The resulting vaccine is a homogeneous white emulsion. Example 5. To obtain microbacterial antigen - leukocidin - exotoxin take production strain Fusobacterium necrophorum "0-1" VIEW, cultivate, inactivate formalin at a final concentration of 0.4%, separating backass from the culture fluid by centrifugation, and the culture fluid secrete an exotoxin, subjected to high purification by ultrafiltration in hollow fibers with a pore size 13-17 kDa and concentrated to a protein content (Lowry) 5,5-7,0 mg% with a molecular mass of 18-20 kDa. Next, to the resulting antigen - leukocidin - endotoxin add 1-10% inactivated bacterial mass strains of Fusobacterium necrophorum "0-1" VIEW content of 7.0-7.7 billion cells in 1 cm3then adsorb on 12-15% aluminum hydroxide in glycolic acid buffer with a pH of 8.4 and 8.6, taken at a final concentration of 1.8 to 3.0%. After adsorption of the antigen on the hydrate of alumina check the neutralization of the residual formalin. To 54.0 per g of inactivated by formalin leukocidin - exotoxin with mm 18-20 kDa from strains of Fusobacterium necrophorum "0-1" VIEW protein content of 5.5 mg%adsorbed 12% aluminum hydroxide in glycolic acid buffer with a pH of 8.4, taken at a final concentration of 1.8%, add 1.0 g of a suspension of live spores of the anthrax vaccine strain 55-Vniivvim with the initial concentration (of 2.5-3.0)×1071 cm3saline solution, 10.0 g of saponin, 20,0 g of glycerin and 15.0 g of a mixture of mineral oils Marcol-52 and OP-10, taken in the weight ratio 1:0,9 receiving part 5 in the following ratio, wt.%:
The vaccine emuleret in the homogenizer at 3500 rpm for 15 minutes The resulting vaccine is a homogeneous white emulsion. Example 6. To obtain microbacterial antigen - leukocidin - exotoxin take production strain Fusobacterium necrophorum "0-1" VIEW, cultivate, inactivate formalin at a final concentration of 0.4%, separating backass from the culture fluid by centrifugation from the culture fluid secrete an exotoxin which is subjected to high purification by ultrafiltration in hollow fibers with a pore size 13-17 kDa and concentrated to a protein content (Lowry) 5,5-7,0 mg% with m the molecular weight of 18-20 kDa. Next, to the resulting antigen - leukocidin - endotoxin add 1-10% inactivated bacterial mass strains of Fusobacterium necrophorum "0-1" VIEW content of 7.0-7.7 billion cells in 1 cm3then adsorb on 12-15% aluminum hydroxide in glycolic acid buffer with a pH of 8.4 and 8.6, taken at a final concentration of 1.8 to 3.0%. After adsorption of the antigen on the hydrate of alumina check the neutralization of the residual formalin. To 33,8 g inactivated by formalin leukocidin - exotoxin with mm 18-20 kDa from strains of Fusobacterium necrophorum "0-1" VIEW protein content of 7.0 mg%adsorbed 15% aluminum hydroxide in glycolic acid buffer with a pH of 8.4 and 8.6, taken at a final concentration of 3.0%, add 1.2 g of a suspension of live spores of the anthrax vaccine strain 55-Vniivvim with the initial concentration (of 2.5-3.0)×1071 cm3saline solution, 15 g of saponin, 30.0 g of glycerin and 20.0 g of a mixture of mineral oils Marcol-52 and OP-10, taken in the weight ratio 1:1,1 receiving part 6 in the following ratio, wt.%:
The vaccine emuleret in the homogenizer at 5000 rpm for 20 minutes The resulting vaccine is a homogeneous white emulsion. Example 7. Obtained by the compositions of examples 1-6 1-6 is used for preventive and forced vaccinations clinically healthy animals once. Calves under 3 months of age, instill the associated vaccine is not permitted. The vaccine is administered intradermally using a needleless injector in hairless area of the body to cattle and pigs 0.4 cm3(2 times, 0.2 cm3), sheep, goats and the reindeers 0.2, see Resistance to infection anthrax and microbacterium saved up to 1.5 years, 1.5 times longer than the known vaccine (obtained by prototype) - h is confirmed by the data on the table. Table. Comparison of indicators of immunogenicity known and offer vaccines against anthrax and nitrobacteria through 1.5 years after vaccination deer in the Republic of Sakha (Yakutia).
Thus, the associated vaccine against anthrax and microbacteria is a highly effective drug, capable of more long-term to protect animals against anthrax and nitrobacteria. 1. A vaccine against anthrax and nitrobacteria containing an inactivated by formalin-leukocidin - exotoxin that results from the production of strains of Fusobacterium necrophorum "0-1" VIEW, representing a highly purified protein with a molecular mass of 18-20 kDa and adsorbed on aluminium hydroxide, and the suspension of live spores of the anthrax vaccine strain 55-Vniivvim in saline and adjuvant, characterized in that the suspension of live spores si is ireasoning vaccine strain 55-Vniivvim use with the initial concentration (of 2.5-3.0)×10 71 cm3saline, optionally contains 1 to 10% inactivated bacterial mass strains of Fusobacterium necrophorum "0-1" VIEW content of 7.0-7.7 billion cells in 1 cm3, glycerin and a mixture of mineral oil "Marcol-52" and emulsifier, taken in the weight ratio 1:(0,9-1,1), respectively, in the following ratio, wt.%:
2. A vaccine against anthrax and nitrobacteria according to claim 1, characterized in that the emulsifier contains emulsifier-139 or ethoxylated With7-C10alkyl phenol. 3. A method of obtaining a vaccine against anthrax and nitrobacteria by culturing strains of Fusobacterium necrophorum "0-1" VIEW, inaktivirovanie his formalin, division of bacterial mass from the culture fluid by centrifugation, separation from the culture fluid of exotoxin - leukocidin, purification, concentration by ultrafiltration in hollow fibers and adsorption on aluminium hydroxide in glycol buffer, adding a suspension of live spores of the anthrax vaccine strain 55-Vniivvim and saponin, characterized in that before adsorption on aluminium hydroxide to the exotoxin add 1-10% inactivated bacterial mass strains of Fusobacterium necrophorum "0-1" VIEW content of 7.0-7.7 billion cells in 1 cm3and glycerin and a mixture of mineral oil "Marcol-52" and emulsifier, taken in the weight ratio 1:(0,9-1,1), respectively, added after the addition of saponin.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||